Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours

Chin Chen Pan, P. C H Chen, L. S. Wang, J. Y. Lee, H. Chiang

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Aims: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF.1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether the information on HER-2/neu would be valuable in identifying patients who are eligible for anti-HER-2/neu treatment. Methods and results: Immunohistochemical stains were performed on 16 cases of non-neoplastic thymus, 63 thymomas and 17 thymic carcinomas. Fluorescence in-situ hybridization (FISH) for HER2 was performed to validate the gene amplification. Eighteen thymomas were positive for p53 and 14 of them were low-expressors, with positive cells below 10%. All thymic carcinomas revealed over-expression of p53 with positive cells either between 10% and 50% or >50%. The expression of p53 correlated with histological type and stage in thymoma. In both thymoma and thymic carcinoma, there was a statistically significant correlation between p53 status and resectability, with low expressors having a higher likelihood of being resectable. Thymic carcinomas, regardless of the histological subtypes, uniformly expressed Bcl-2, while thymomas showed no or only weak cytoplasmic immunoreactivity. Most thymomas and thymic carcinomas were negative for Bcl-XL, p21WAF.1/CIP1 and cyclin D1. The expression of BAX was inconsistent among different histological types. Nine thymic carcinomas revealed membranous positivity for HER-2/neu. but no HER2 gene amplification could be demonstrated by FISH in any of the cases. Conclusions: p53 and Bcl-2 are more implicated in the development of thymic carcinoma than thymoma. The higher level of p53 expression and the strong immunopositive pattern of Bcl-2 in thymic carcinomas have potential value in the differential diagnosis and prediction of aggressiveness and resectability. On account of the absence of HER2 amplification, patients would probably not benefit from anti-HER-2/neu treatment.

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalHistopathology
Volume43
Issue number2
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

Fingerprint

Thymoma
Apoptosis
Gene Amplification
Cyclin D1
Thymic epithelial tumor
Fluorescence In Situ Hybridization
erbB-2 Genes
Oncogenes
Thymus Gland

Keywords

  • Apoptosis
  • Bcl-2
  • Fluorescence in-situ hybridization
  • HER-2/neu
  • Immunohistochemistry
  • p53
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Cell Biology
  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. / Pan, Chin Chen; Chen, P. C H; Wang, L. S.; Lee, J. Y.; Chiang, H.

In: Histopathology, Vol. 43, No. 2, 01.08.2003, p. 165-172.

Research output: Contribution to journalArticle

Pan, Chin Chen ; Chen, P. C H ; Wang, L. S. ; Lee, J. Y. ; Chiang, H. / Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. In: Histopathology. 2003 ; Vol. 43, No. 2. pp. 165-172.
@article{0bd188f2bf8b482d8826b90798cf83d7,
title = "Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours",
abstract = "Aims: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF.1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether the information on HER-2/neu would be valuable in identifying patients who are eligible for anti-HER-2/neu treatment. Methods and results: Immunohistochemical stains were performed on 16 cases of non-neoplastic thymus, 63 thymomas and 17 thymic carcinomas. Fluorescence in-situ hybridization (FISH) for HER2 was performed to validate the gene amplification. Eighteen thymomas were positive for p53 and 14 of them were low-expressors, with positive cells below 10{\%}. All thymic carcinomas revealed over-expression of p53 with positive cells either between 10{\%} and 50{\%} or >50{\%}. The expression of p53 correlated with histological type and stage in thymoma. In both thymoma and thymic carcinoma, there was a statistically significant correlation between p53 status and resectability, with low expressors having a higher likelihood of being resectable. Thymic carcinomas, regardless of the histological subtypes, uniformly expressed Bcl-2, while thymomas showed no or only weak cytoplasmic immunoreactivity. Most thymomas and thymic carcinomas were negative for Bcl-XL, p21WAF.1/CIP1 and cyclin D1. The expression of BAX was inconsistent among different histological types. Nine thymic carcinomas revealed membranous positivity for HER-2/neu. but no HER2 gene amplification could be demonstrated by FISH in any of the cases. Conclusions: p53 and Bcl-2 are more implicated in the development of thymic carcinoma than thymoma. The higher level of p53 expression and the strong immunopositive pattern of Bcl-2 in thymic carcinomas have potential value in the differential diagnosis and prediction of aggressiveness and resectability. On account of the absence of HER2 amplification, patients would probably not benefit from anti-HER-2/neu treatment.",
keywords = "Apoptosis, Bcl-2, Fluorescence in-situ hybridization, HER-2/neu, Immunohistochemistry, p53, Thymic carcinoma, Thymoma",
author = "Pan, {Chin Chen} and Chen, {P. C H} and Wang, {L. S.} and Lee, {J. Y.} and H. Chiang",
year = "2003",
month = "8",
day = "1",
doi = "10.1046/j.1365-2559.2003.01663.x",
language = "English",
volume = "43",
pages = "165--172",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours

AU - Pan, Chin Chen

AU - Chen, P. C H

AU - Wang, L. S.

AU - Lee, J. Y.

AU - Chiang, H.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Aims: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF.1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether the information on HER-2/neu would be valuable in identifying patients who are eligible for anti-HER-2/neu treatment. Methods and results: Immunohistochemical stains were performed on 16 cases of non-neoplastic thymus, 63 thymomas and 17 thymic carcinomas. Fluorescence in-situ hybridization (FISH) for HER2 was performed to validate the gene amplification. Eighteen thymomas were positive for p53 and 14 of them were low-expressors, with positive cells below 10%. All thymic carcinomas revealed over-expression of p53 with positive cells either between 10% and 50% or >50%. The expression of p53 correlated with histological type and stage in thymoma. In both thymoma and thymic carcinoma, there was a statistically significant correlation between p53 status and resectability, with low expressors having a higher likelihood of being resectable. Thymic carcinomas, regardless of the histological subtypes, uniformly expressed Bcl-2, while thymomas showed no or only weak cytoplasmic immunoreactivity. Most thymomas and thymic carcinomas were negative for Bcl-XL, p21WAF.1/CIP1 and cyclin D1. The expression of BAX was inconsistent among different histological types. Nine thymic carcinomas revealed membranous positivity for HER-2/neu. but no HER2 gene amplification could be demonstrated by FISH in any of the cases. Conclusions: p53 and Bcl-2 are more implicated in the development of thymic carcinoma than thymoma. The higher level of p53 expression and the strong immunopositive pattern of Bcl-2 in thymic carcinomas have potential value in the differential diagnosis and prediction of aggressiveness and resectability. On account of the absence of HER2 amplification, patients would probably not benefit from anti-HER-2/neu treatment.

AB - Aims: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF.1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether the information on HER-2/neu would be valuable in identifying patients who are eligible for anti-HER-2/neu treatment. Methods and results: Immunohistochemical stains were performed on 16 cases of non-neoplastic thymus, 63 thymomas and 17 thymic carcinomas. Fluorescence in-situ hybridization (FISH) for HER2 was performed to validate the gene amplification. Eighteen thymomas were positive for p53 and 14 of them were low-expressors, with positive cells below 10%. All thymic carcinomas revealed over-expression of p53 with positive cells either between 10% and 50% or >50%. The expression of p53 correlated with histological type and stage in thymoma. In both thymoma and thymic carcinoma, there was a statistically significant correlation between p53 status and resectability, with low expressors having a higher likelihood of being resectable. Thymic carcinomas, regardless of the histological subtypes, uniformly expressed Bcl-2, while thymomas showed no or only weak cytoplasmic immunoreactivity. Most thymomas and thymic carcinomas were negative for Bcl-XL, p21WAF.1/CIP1 and cyclin D1. The expression of BAX was inconsistent among different histological types. Nine thymic carcinomas revealed membranous positivity for HER-2/neu. but no HER2 gene amplification could be demonstrated by FISH in any of the cases. Conclusions: p53 and Bcl-2 are more implicated in the development of thymic carcinoma than thymoma. The higher level of p53 expression and the strong immunopositive pattern of Bcl-2 in thymic carcinomas have potential value in the differential diagnosis and prediction of aggressiveness and resectability. On account of the absence of HER2 amplification, patients would probably not benefit from anti-HER-2/neu treatment.

KW - Apoptosis

KW - Bcl-2

KW - Fluorescence in-situ hybridization

KW - HER-2/neu

KW - Immunohistochemistry

KW - p53

KW - Thymic carcinoma

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=0041659114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041659114&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2559.2003.01663.x

DO - 10.1046/j.1365-2559.2003.01663.x

M3 - Article

C2 - 12877732

AN - SCOPUS:0041659114

VL - 43

SP - 165

EP - 172

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 2

ER -